Quarterly Earnings

Arlo Technologies smashed expectations with record revenue, fueled by a masterful pivot to recurring services that now form the core of its business.

With nearly $1B in cash and a shrinking net loss, Janux is pushing its advanced prostate cancer drugs while its novel autoimmune therapy nears a key data reveal.

Doximity's Q1 results reveal a company at a crossroads, sacrificing near-term profits for AI dominance. Engagement is soaring, but financials are strained.

Clipper Realty's latest earnings reveal a stark divide. Record-breaking residential rents are being overshadowed by a major commercial property default.

With a $215M war chest and a runway into 2028, Corvus Pharmaceuticals is aggressively advancing its lead drug, soquelitinib, across cancer and immune diseases.

Outset Medical's Q2 results reveal a pivotal moment: a major HCA deal and stronger margins point to a new phase of sustainable growth in the dialysis market.

Stunning 120% revenue growth validates Senseonics' shift to in-house sales, but soaring costs and a widening net loss raise critical questions about its path to profitability.

International Bancshares reports steady half-year growth but a Q2 dip, revealing a strategy of proactive risk management and AI-driven efficiency.

Argentina's top cement firm posts a staggering profit jump, but a deeper analysis reveals operational struggles and a construction sector at a crossroads.

Beyond record revenues, Russel Metals' latest report shows a masterclass in strategy. A key acquisition is paying off big, and its performance is a bellwether for a resurgent U.S. industrial economy.

Despite a net loss, Drilling Tools International's Q2 results show surprising strength, driven by innovative tech and robust free cash flow.

The luxury resale giant posted a record quarter and raised its 2026 forecast, but a wider GAAP loss tells a more complex story of strategic growth.

Genpact's stellar Q2 results are more than just numbers; they're proof of a strategic pivot to 'Agentic Operations' that could reshape the BPO landscape.

Biotech firm MetaVia reports progress on its obesity drug DA-1726, with patients reaching high doses. Promising early data sets the stage for a pivotal Q4 readout.

Cryoport hits a key profitability milestone, but the real story is its tightening grip on the booming gene therapy market. Is this a true turning point?

Amphastar beats Q2 estimates with new drug sales, but a deeper look reveals pricing pressure, rising costs, and a high-stakes bet on its pipeline.

A reported net loss obscures core growth at 10x Genomics. An acquisition, key partnerships, and a blockbuster product launch signal a decisive strategic pivot.

After Commerce.com's dismal Q2 results and stock plunge, AI-native rival Rezolve Ai declares its rejected merger proposal was the right path all along.

Where Food Comes From boosts profits via efficiency and new certifications like RaiseWell, offsetting beef market pressures and digital asset swings.

Aéroports de Montréal is pouring billions into a massive overhaul of YUL, even as U.S. travel slumps. A look at the high-stakes gamble on future growth.